Cost controls help Merck beat profit forecast (Reuters via Yahoo! News)
Merck & Co on Monday reported better-than-expected quarterly earnings as tight cost controls offset plunging sales of an osteoporosis drug now facing generic competition and slowing sales growth of its Vytorin and Zetia cholesterol fighters.